Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| <p>Regulatory networks of HIFs in tumor‑infiltrating immune cells: From molecular mechanisms to therapeutic implications (Review)</p>. | Int J Oncol | 2026 | 41543185 | PubTator, text mining | PubMed |
| Persistent Immune Dysregulation during Long COVID is Manifested in Antibodies Targeting Envelope and Nucleocapsid Proteins. | Res Sq | 2026 | 41542038 | PubTator, text mining | PubMed |
| The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia. | Blood | 2026 | 41528026 | PubTator, text mining | PubMed |
| Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B-cell-related epigenetic imprinting and genetic alterations. | Hemasphere | 2026 | 41523081 | PubTator, text mining | PubMed |
| First-line treatment for CLL in the era of targeted therapy. | Blood Cancer J | 2026 | 41507154 | PubTator, text mining | PubMed |
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group. | EClinicalMedicine | 2026 | 41502925 | PubTator, text mining | PubMed |
| Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland. | Clin Lymphoma Myeloma Leuk | 2026 | 41484009 | PubTator, text mining | PubMed |
| Double IGHV rearrangements in a Latin American cohort of chronic lymphocytic leukemia patients. | Leuk Res | 2026 | 41443145 | PubTator, text mining | PubMed |
| A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study. | Blood | 2026 | 41405491 | PubTator, text mining | PubMed |
| Reply to "Methylation-based droplet digital polymerase chain reaction shows high concordance with chronic lymphocytic leukemia IGHV somatic mutation status". | Am J Clin Pathol | 2026 | 41346081 | PubTator, text mining | PubMed |
| Immunophenotypic, cytogenetic, and mutational features of chronic lymphocytic leukemia/small lymphocytic lymphoma with atypical immunophenotype. | Cytometry B Clin Cytom | 2026 | 40814768 | PubTator, text mining | PubMed |
| CD6 expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia. | Haematologica | 2026 | 40605694 | PubTator, text mining | PubMed |
| A RARE DETERMINATION OF SMALL LYMPHOCYTIC LYMPHOMA ASSOCIATED WITH UNFAVORABLE EVOLUTION AND REVIEW OF THE LITERATURE. | Acta Endocrinol (Buchar) | 2025 | 42569653 | PubTator, text mining | PubMed |
| MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms. | Semin Hematol | 2025 | 42014240 | PubTator, text mining | PubMed |
| Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia? | Acta Medica (Hradec Kralove) | 2025 | 41873918 | PubTator, text mining | PubMed |
| B cell phenotypes and antibody signatures associate with interpatient variation in the lung adenocarcinoma tumor microenvironment. | Front Immunol | 2025 | 41684542 | PubTator, text mining | PubMed |
| Low IgE and absence of sensitization in non-T2 asthma: a transcriptomic and cytokine study. | Front Immunol | 2025 | 41601686 | PubTator, text mining | PubMed |
| Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. | Cureus | 2025 | 41573489 | PubTator, text mining | PubMed |
| Integrating flow cytometric profile and gene mutation analysis of intact lymph nodes to refine lymphoma immunophenotype. | Am J Transl Res | 2025 | 41552297 | PubTator, text mining | PubMed |
Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China. | EClinicalMedicine | 2025 | 41497516 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=4